Datapoint: FDA Grants J&J’s Carvykti Earlier, Expanded Use in Multiple Myeloma

The FDA last week expanded Johnson & Johnson and Legend Biotech’s Carvykti’s (ciltacabtagene autoleucel; cilta-cel) use in multiple myeloma patients, moving from third line to second line. The CAR-T drug is now the first BCMA-directed therapy available to treat relapsed or refractory multiple myeloma in adult patients who have received at least one prior line of therapy. Phase 3 trial data showed Carvykti reduced the risk of disease progression and death by 59%. For the treatment of multiple myeloma, the drug is covered for most insured lives in the U.S. 21% have covered access to Carvykti under the medical benefit, while an additional 73% have covered access with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 4/8/24

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 16

Datapoint: Cigna, Oscar to End Small Group Partnership

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 15

Datapoint: FDA Approves Pfizer’s Hemophilia B Treatment

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 14

Datapoint: Sandoz Reaches Agreement With Amgen to Launch Prolia, Xgeva Biosimilars

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today